Medicare Approves Coverage for DiaCarta's RadTox™ Test for Tumor Response Monitoring

Wednesday, February 21, 2024

DiaCarta, a prominent molecular diagnostics firm focused on tailoring patient care through liquid biopsy, has proudly unveiled its innovative RadTox™ test, designed to monitor tumor response during cancer treatment. The RadTox™ test represents a pioneering approach in cancer therapy monitoring, utilizing the measurement of cell-free DNA (cfDNA) levels, which elevate in cancer patients due to the rapid proliferation of cells and apoptosis.

DiaCarta's proprietary technology enables the direct quantification of cfDNA in blood without the need for sample purification, amplifying chemical signals labeled on specific probes. This novel method allows for real-time evaluation of tumor response, providing critical insights into treatment effectiveness for physicians.

Unlike conventional molecular residual disease (MRD) monitoring, which targets specific tumor mutant clones post-treatment, RadTox™ offers a broader perspective by analyzing changes in cfDNA levels. This enables physicians to make informed decisions and personalize treatment strategies based on comprehensive data.

Patients undergoing treatments such as radiotherapy or chemotherapy often require immediate feedback on treatment efficacy. The integration of RadTox™ into standard clinical practice signifies a significant advancement in cancer care, empowering clinicians with timely insights to optimize patient outcomes.




Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital Congress